Gavyza for CLL – pro
GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia. Bt itself, is is also quite effective. A study of two different doses of single-agent obinutuzumab, showed a strong trend to a better response with the higher dose, especially as regards complete responses. Similarly, the GAUSS study, a randomized phase 2 study comparing obinutuzumab with rituximab in patients with relapsed indolent B-cell lymphoma, showed that Obinutuzumab resulted in higher overall response rates as assessed by both investigators (44% vs 38%; NS) and a blinded independent review facility (43% vs 28%; P < .01).
Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012;119(16):3698-3704
Sehn LH, Goy A, Offner FC, et al. Randomized phase 2 trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS Study. Blood (ASH Annual Meeting Abstracts) 2011;118:269.